Table 2.
Triple-negative breast cancers cases: distribution according to miR-30a (5p and 3p) expression, demographics and clinical pathological features
| miR-30a-5p | miR-30a-3p | ||||||
|---|---|---|---|---|---|---|---|
| Total (N=59) | Lowa (N=29) | Higha (N=30) | P-value | Lowa (N=29) | Higha (N=30) | P-value | |
| Median follow-up (months) | 63.2 | 61.0 | 65.4 | 0.87c | 51.3 | 67.7 | 0.06c |
| Median age at diagnosis (yrs) | 51 | 49 | 52 | 0.50c | 52 | 50 | 0.13c |
| No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | |||
| Tumor sizeb | |||||||
| T1 | 28 (52.8) | 12 (42.9) | 16 (64.0) | 0.09d | 11 (39.3) | 17 (68.0) | 0.06d |
| T2 | 22 (41.5) | 13 (46.4) | 9 (36.0) | 14 (50.0) | 8 (32.0) | ||
| T3–T4 | 3 (5.7) | 3 (10.7) | 0 (0.0) | 3 (10.7) | 0 (0.0) | ||
| Lymph nodesb | |||||||
| N0 | 28 (47.5) | 10 (35.7) | 18 (75.0) | 0.01d | 9 (32.1) | 19 (79.2) | <0.001d |
| N+ | 24 (40.7) | 18 (64.3) | 6 (25.0) | 19 (67.9) | 5 (20.8) | ||
| Metastasis | |||||||
| M0 | 54 (91.5) | 28 (96.6) | 26 (86.7) | 0.35d | 27 (93.1) | 27 (90.0) | 1.00d |
| M+ | 5 (8.5) | 1 (3.5) | 4 (13.3) | 2 (6.9) | 4 (10.0) | ||
| TNM stage | |||||||
| I | 19 (32.2) | 8 (27.6) | 11 (36.7) | 0.80d | 7 (24.1) | 12 (40.0) | 0.43d |
| II | 25 (42.4) | 13 (44.8) | 12 (40.0) | 13 (44.8) | 12 (40.0) | ||
| III–IV | 15 (25.4) | 8 (27.6) | 7 (23.3) | 9 (31.0) | 6 (20.0) | ||
| Tumor gradeb | |||||||
| G1–G2 | 3 (5.1) | 1 (3.6) | 2 (6.7) | 1.00d | 0 (0.0) | 3 (10.4) | 0.24d |
| G3 | 55 (93.2) | 27 (96.4) | 28 (93.3) | 29 (100.0) | 26 (89.7) | ||
| Radiation treatmentb | |||||||
| No | 23 (45.1) | 10 (38.5) | 13 (52.0) | 0.40d | 11 (45.8) | 12 (55.6) | 1.00d |
| Yes | 28 (54.9) | 16 (61.5) | 12 (48.0) | 13 (54.2) | 15 (44.4) | ||
| Pharmacological treatmentb | |||||||
| No | 9 (16.1) | 3 (11.1) | 6 (20.7) | 0.47d | 4 (14.8) | 5 (17.2) | 1.00d |
| Yes | 47 (83.9) | 24 (88.9) | 23 (79.3) | 23 (85.2) | 24 (82.8) | ||
| Drugsb | |||||||
| Anthracycline | 21 (47.7) | 14 (60.9) | 7 (33.3) | 0.23d | 11 (52.4) | 10 (43.5) | 0.73d |
| Anthracycline/Taxanes | 11 (25.0) | 4 (17.4) | 7 (33.3) | 4 (19.0) | 7 (30.4) | ||
| CMF | 12 (27.3) | 5 (21.7) | 7 (33.3) | 6 (28.6) | 6 (26.1) | ||
CMF cyclophosphamide, methotrexate and 5-fluorouracil
aThe median value was used as cut-off
bThe sum does not add up to the total because of some missing values
cMann–Whitney–Wilcoxon test
dFisher’s exact test